Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
ChemMedChem ; 14(14): 1321-1324, 2019 07 17.
Article in English | MEDLINE | ID: mdl-31183991

ABSTRACT

We recently identified AG1, a small-molecule activator that functions by promoting oligomerization of glucose-6-phosphate dehydrogenase (G6PD) to the catalytically competent forms. Biochemical experiments indicate that the activation of G6PD by the original hit molecule (AG1) is noncovalent and that one C2 -symmetric region of the G6PD homodimer is important for ligand function. Consequently, the disulfide in AG1 is not required for activation of G6PD, and a number of analogues were prepared without this reactive moiety. Our study supports a mechanism of action whereby AG1 bridges the dimer interface at the structural nicotinamide adenine dinucleotide phosphate (NADP+ ) binding sites of two interacting G6PD monomers. Small molecules that promote G6PD oligomerization have the potential to provide a first-in-class treatment for G6PD deficiency. This general strategy could be applied to other enzyme deficiencies in which control of oligomerization can enhance enzymatic activity and/or stability.


Subject(s)
Enzyme Activators/metabolism , Glucosephosphate Dehydrogenase/metabolism , Indoles/metabolism , Binding Sites , Enzyme Activators/chemical synthesis , Glucosephosphate Dehydrogenase/chemistry , Glucosephosphate Dehydrogenase/genetics , Humans , Indoles/chemical synthesis , Ligands , Molecular Docking Simulation , Mutation , NADP/chemistry , NADP/metabolism , Protein Binding , Protein Multimerization/drug effects
2.
Cell Rep ; 18(11): 2592-2599, 2017 03 14.
Article in English | MEDLINE | ID: mdl-28297664

ABSTRACT

G6PD deficiency, an enzymopathy affecting 7% of the world population, is caused by over 160 identified amino acid variants in glucose-6-phosphate dehydrogenase (G6PD). The clinical presentation of G6PD deficiency is diverse, likely due to the broad distribution of variants across the protein and the potential for multidimensional biochemical effects. In this study, we use bioinformatic and biochemical analyses to interpret the relationship between G6PD variants and their clinical phenotype. Using structural information and statistical analyses of known G6PD variants, we predict the molecular phenotype of five uncharacterized variants from a reference population database. Through multidimensional analysis of biochemical data, we demonstrate that the clinical phenotypes of G6PD variants are largely determined by a trade-off between protein stability and catalytic activity. This work expands the current understanding of the biochemical underpinnings of G6PD variant pathogenicity and suggests a promising avenue for correcting G6PD deficiency by targeting essential structural features of G6PD.


Subject(s)
Biocatalysis , Glucosephosphate Dehydrogenase/genetics , Glucosephosphate Dehydrogenase/metabolism , Mutation/genetics , Amino Acid Substitution , Databases, Protein , Glucosephosphate Dehydrogenase/chemistry , Humans , Models, Molecular , Principal Component Analysis , Protein Stability
3.
Curr Opin Struct Biol ; 44: 59-66, 2017 06.
Article in English | MEDLINE | ID: mdl-28063303

ABSTRACT

Protein-protein interactions are essential for almost all intracellular and extracellular biological processes. Regulation of protein-protein interactions is one strategy to regulate cell fate in a highly selective manner. Specifically, peptides are ideal candidates for inhibition of protein-protein interactions because they can mimic a protein surface to effectively compete for binding. Additionally, peptides are synthetically accessible and can be stabilized by chemical modifications. In this review, we survey screening and rational design methods for identifying peptides to inhibit protein-protein interactions, as well as methods for stabilizing peptides to effectively mimic protein surfaces. In addition, we discuss recent applications of peptides to regulate protein-protein interactions for both basic research and therapeutic purposes.


Subject(s)
Drug Discovery/methods , Peptides/pharmacology , Peptidomimetics/pharmacology , Amino Acid Sequence , Animals , Humans , Molecular Targeted Therapy , Peptides/chemistry , Peptidomimetics/chemistry , Protein Binding , Protein Structure, Secondary
4.
Matters (Zur) ; 20172017 Sep 14.
Article in English | MEDLINE | ID: mdl-30148135

ABSTRACT

Over 220 different amino acid variants have been identified in human glucose-6-phosphate dehydrogenase (G6PD), covering over 30% of the protein sequence. Many of these variants are pathogenic, causing varying degrees of G6PD deficiency with symptoms ranging from severe chronic anemia (class I) to milder triggered hemolytic episodes (classes II and III). The phenotypic effects of most G6PD variants have been reported, providing an opportunity to correlate phenotypic and structural information. In particular, we sought to investigate the tetramer interface of G6PD in relation to pathogenic variation, as there are conflicting reports indicating the importance of tetramerization for G6PD activity. Using a three-dimensional spatial scan statistic, hotspots of structural enrichment were identified for each class of pathogenic G6PD variants. Class I variants, the most phenotypically severe, were enriched at the dimer interface, consistent with previous evidence that dimerization is essential for G6PD activity. Class II variants were enriched near the tetramer interface, suggesting that tetramerization is also important for G6PD activity. This analysis explains why these two classes, both yielding 10% or less G6PD activity as compared to normal, lead to different clinical outcomes.

5.
Clin Perinatol ; 43(2): 341-54, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27235212

ABSTRACT

Hyperbilirubinemia occurs frequently in newborns, and in severe cases can progress to kernicterus and permanent developmental disorders. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human enzymopathies, is a major risk factor for hyperbilirubinemia and greatly increases the risk of kernicterus even in the developed world. Therefore, a novel treatment for kernicterus is needed, especially for G6PD-deficient newborns. Oxidative stress is a hallmark of bilirubin toxicity in the brain. We propose that the activation of G6PD via a small molecule chaperone is a potential strategy to increase endogenous defense against bilirubin-induced oxidative stress and prevent kernicterus.


Subject(s)
Antioxidants/therapeutic use , Glucosephosphate Dehydrogenase Deficiency/metabolism , Hyperbilirubinemia, Neonatal/therapy , Kernicterus/prevention & control , Molecular Chaperones/therapeutic use , Phototherapy , Glucosephosphate Dehydrogenase Deficiency/complications , Humans , Hyperbilirubinemia, Neonatal/complications , Hyperbilirubinemia, Neonatal/metabolism , Infant, Newborn , Kernicterus/etiology , Kernicterus/metabolism , Kernicterus/therapy
6.
Int J Parasitol Drugs Drug Resist ; 6(1): 74-84, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27054066

ABSTRACT

Parasitic diseases cause ∼ 500,000 deaths annually and remain a major challenge for therapeutic development. Using a rational design based approach, we developed peptide inhibitors with anti-parasitic activity that were derived from the sequences of parasite scaffold proteins LACK (Leishmania's receptor for activated C-kinase) and TRACK (Trypanosoma receptor for activated C-kinase). We hypothesized that sequences in LACK and TRACK that are conserved in the parasites, but not in the mammalian ortholog, RACK (Receptor for activated C-kinase), may be interaction sites for signaling proteins that are critical for the parasites' viability. One of these peptides exhibited leishmanicidal and trypanocidal activity in culture. Moreover, in infected mice, this peptide was also effective in reducing parasitemia and increasing survival without toxic effects. The identified peptide is a promising new anti-parasitic drug lead, as its unique features may limit toxicity and drug-resistance, thus overcoming central limitations of most anti-parasitic drugs.


Subject(s)
Leishmania/drug effects , Peptides/chemical synthesis , Peptides/pharmacology , Protozoan Proteins/antagonists & inhibitors , Receptors, Cell Surface/antagonists & inhibitors , Trypanocidal Agents/pharmacology , Trypanosoma/drug effects , Amino Acid Sequence , Animals , Antigens, Protozoan/chemistry , Drug Design , Leishmania/chemistry , Leishmania/genetics , Leishmaniasis/drug therapy , Leishmaniasis/parasitology , Mice , Parasitemia/drug therapy , Peptides/administration & dosage , Protozoan Proteins/chemistry , Receptors for Activated C Kinase , Receptors, Cell Surface/chemistry , Sequence Alignment , Trypanocidal Agents/administration & dosage , Trypanocidal Agents/chemistry , Trypanosoma/genetics , Trypanosomiasis/drug therapy , Trypanosomiasis/parasitology
7.
J Biol Chem ; 291(26): 13608-21, 2016 Jun 24.
Article in English | MEDLINE | ID: mdl-27129213

ABSTRACT

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an important glycolytic enzyme, has a non-catalytic (thus a non-canonical) role in inducing mitochondrial elimination under oxidative stress. We recently demonstrated that phosphorylation of GAPDH by δ protein kinase C (δPKC) inhibits this GAPDH-dependent mitochondrial elimination. δPKC phosphorylation of GAPDH correlates with increased cell injury following oxidative stress, suggesting that inhibiting GAPDH phosphorylation should decrease cell injury. Using rational design, we identified pseudo-GAPDH (ψGAPDH) peptide, an inhibitor of δPKC-mediated GAPDH phosphorylation that does not inhibit the phosphorylation of other δPKC substrates. Unexpectedly, ψGAPDH decreased mitochondrial elimination and increased cardiac damage in an animal model of heart attack. Either treatment with ψGAPDH or direct phosphorylation of GAPDH by δPKC decreased GAPDH tetramerization, which corresponded to reduced GAPDH glycolytic activity in vitro and ex vivo Taken together, our study identified the potential mechanism by which oxidative stress inhibits the protective GAPDH-mediated elimination of damaged mitochondria. Our study also identified a pharmacological tool, ψGAPDH peptide, with interesting properties. ψGAPDH peptide is an inhibitor of the interaction between δPKC and GAPDH and of the resulting phosphorylation of GAPDH by δPKC. ψGAPDH peptide is also an inhibitor of GAPDH oligomerization and thus an inhibitor of GAPDH glycolytic activity. Finally, we found that ψGAPDH peptide is an inhibitor of the elimination of damaged mitochondria. We discuss how this unique property of increasing cell damage following oxidative stress suggests a potential use for ψGAPDH peptide-based therapy.


Subject(s)
Enzyme Inhibitors/pharmacology , Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/antagonists & inhibitors , Glycolysis/drug effects , Peptides/pharmacology , Protein Kinase C-delta/metabolism , Animals , Cell Death/drug effects , Cell Line , Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/genetics , Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/metabolism , Glycolysis/physiology , Humans , Male , Mice , Phosphorylation/drug effects , Phosphorylation/physiology , Protein Kinase C-delta/genetics , Protein Multimerization/drug effects , Rats , Rats, Wistar , Zebrafish
SELECTION OF CITATIONS
SEARCH DETAIL